198 related articles for article (PubMed ID: 29391567)
1. Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.
Evans M; Methven S; Gasparini A; Barany P; Birnie K; MacNeill S; May MT; Caskey FJ; Carrero JJ
Sci Rep; 2018 Feb; 8(1):2103. PubMed ID: 29391567
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
3. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
[TBL] [Abstract][Full Text] [Related]
5. Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital.
Sin HY
J Clin Pharm Ther; 2017 Oct; 42(5):607-614. PubMed ID: 28585333
[TBL] [Abstract][Full Text] [Related]
6. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Fukagawa M; Shimazaki R; Akizawa T;
Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB
PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942
[TBL] [Abstract][Full Text] [Related]
11. Development of evocalcet for unmet needs among calcimimetic agents.
Hamano N; Endo Y; Kawata T; Fukagawa M
Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
[TBL] [Abstract][Full Text] [Related]
12. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
Palmer SC; Nistor I; Craig JC; Pellegrini F; Messa P; Tonelli M; Covic A; Strippoli GF
PLoS Med; 2013; 10(4):e1001436. PubMed ID: 23637579
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
[TBL] [Abstract][Full Text] [Related]
15. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.
Behets GJ; Spasovski G; Sterling LR; Goodman WG; Spiegel DM; De Broe ME; D'Haese PC
Kidney Int; 2015 Apr; 87(4):846-56. PubMed ID: 25337774
[TBL] [Abstract][Full Text] [Related]
16. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease.
Arenas Morales AJ; DeFreitas MJ; Katsoufis CP; Seeherunvong W; Chandar J; Zilleruelo G; Freundlich M; Abitbol CL
Pediatr Nephrol; 2019 Jan; 34(1):129-135. PubMed ID: 30203374
[TBL] [Abstract][Full Text] [Related]
18. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
19. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
20. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
